Therapeutic plasma exchange in neuro-immunological disorder

Authors

  • Aswin Kumar S. Department of Transfusion Medicine, Institute of Child Health and Hospital for Children, Chennai, Tamil Nadu, India
  • Latha B. Department of Transfusion Medicine, Kilpauk Medical College, Chennai, Tamil Nadu, India
  • Dhivya x Dhivya K. Department of Transfusion Medicine, KMC, Manipal, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20171263

Keywords:

Extracorporeal, Neuro-immunological, Myasthenia Gravis, Guillain-Barré Syndrome, Plasma exchange

Abstract

Background: Therapeutic plasma exchange (TPE) is an extracorporeal blood purification technique used to remove high molecular weight substances from the plasma. Examples of these substances include immune complexes, pathogenic autoantibodies, endotoxin, cryoglobulins and cholesterol-containing lipoproteins and myeloma light chains. Therapeutic Plasma exchange is a well-established therapeutic procedure most commonly used in many neuro-immunological disorders. The benefit of plasma exchange occurs by elimination of pathognomonic inflammatory mediators, including complement components, autoantibodies and cytokines. Various studied have demonstrated that TPE plays an important role in neuro-immunological disorder (eg. Guillain-Barré syndrome, myasthenia gravis and other forms of immune neuropathies).

Methods: It is descriptive and prospective study on the effect of TPE in neuro-immunological disorders. TPE are studied prospectively for a period from September 2011 to August 2013. The amount of plasma to be exchanged during TPE was determined using the formula EPV = (0.065 x weight [kg]) x (1-hematocrit). TPE was performed using a Haemonetics MCS+ intermittent flow cell separator. An average of 1-1.5 plasma volume is removed on alternative days. Clinical outcome of TPE was assessed at the time of discharge.

Results: A total of 138 Therapeutic plasma exchange procedure were performed on 30 patients. In which the improvement begins within days of commencing the treatments and progressed steadily so that 25 out of 30 patients who responded favourably to TPE with a manageable adverse reaction. And only 5 patients failed to respond this therapy. So the clinical outcome for therapeutic plasma exchange for Neuro-immunological cases were 83.3% and remaining 16.7% doesn’t show any improvement after five plasma exchanges.

Conclusions: Therapeutic plasma exchange is a first line of management for most of the neuro-immunological disorder. In our study there was an improvement in motor performance after 3-5 plasma exchanges which are mainly due to removal of unbound antibodies from the plasma. Although the statistical power of our study was not sufficient to allow definitive conclusion, the result strongly suggest that 3-5 procedures on alternative days with 1-1.5 volume of plasma exchange gives a better result in patient with neuro-immunlogical diseases. The success of therapeutic plasma exchange also depends on composition of the replacement fluid. The risk and complication associated with procedure are also minimal and easily manageable.

Author Biographies

Aswin Kumar S., Department of Transfusion Medicine, Institute of Child Health and Hospital for Children, Chennai, Tamil Nadu, India

Department of Transfusion Medicine

Latha B., Department of Transfusion Medicine, Kilpauk Medical College, Chennai, Tamil Nadu, India

Department of Transfusion Medicine

References

Petar K, Vanja, Nikolina. Therapeutic plasma exchange in the neurologic intensive care setting recommendation for clinical practice. Acta Clin Croat. 2012;51:137-53.

Tazi I, Merimi F. Therapeutic plasma exchange in Casablanca. Transfusion and Apheresis science 39. 2008:45-48.

Koo AP. Overview of therapeutic apheresis in the USA. Ther Apher. 1999;3:4-7.

Lehmann HC, Hartung HP. Plasma exchange in neuroimmunological disorders. ARCH NEURO. 2006;63:930-5.

Ujjan I. Plasmapheresis technique, complications and indications at the ISRA university hospital Hyderabad. 2011;17(3):57-9.

Hahn AF, Bolton CF. Plasma exchange therapy in chronic inflammatory demyelinating polyneuropathy, a double blind, sham-controlled, cross-over study. Brain. 1996;119:1055-66.

Newsom-Davis J, Wilson SG, Vincent A, Ward CD. Longterm effects of repeated plasma exchange in myasthenia gravis. Lancet. 1979;1(8114):464-8.

Antozzi C, Gemma M, Regi B, Berta E, Confalonieri P, Peluchetti D, et al. A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol. 1991;238(2):103-7.

Behan PO, Shakir RA, Simpson JA, Burnett AK, Allan TL, Haase G. Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis. Lancet. 1979;2(8140):438-40.

Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Siden A, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984;2 (8415):1296-9.

Valbonesi M, Garelli S, Mosconi L, Zerbi D, Celano I. Plasma exchange as a therapy for Guillain-Barre syndrome with immune. complexes. 1981;41(2):74-8.

Newland AC, Ridley A. Treatment of the Guillain-Barre syndrome by plasma Exchange Journal of Neurology, Neurosurgery, and Psychiatry. 1982;45:847-850.

Downloads

Published

2017-03-28

How to Cite

S., A. K., B., L., & Dhivya K., D. x. (2017). Therapeutic plasma exchange in neuro-immunological disorder. International Journal of Research in Medical Sciences, 5(4), 1550–1553. https://doi.org/10.18203/2320-6012.ijrms20171263

Issue

Section

Original Research Articles